guest ::
| Home > Publications database > Tumoral Immune Cell Exploitation in Colorectal Cancer Metastases Can Be Targeted Effectively by Anti-CCR5 Therapy in Cancer Patients. > print |
| Home > Publications database > Tumoral Immune Cell Exploitation in Colorectal Cancer Metastases Can Be Targeted Effectively by Anti-CCR5 Therapy in Cancer Patients. > print |
| 001 | 125953 | ||
| 005 | 20240228143342.0 | ||
| 024 | 7 | _ | |a 10.1016/j.ccell.2016.03.005 |2 doi |
| 024 | 7 | _ | |a pmid:27070705 |2 pmid |
| 024 | 7 | _ | |a 1535-6108 |2 ISSN |
| 024 | 7 | _ | |a 1878-3686 |2 ISSN |
| 024 | 7 | _ | |a altmetric:6616093 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2017-02077 |
| 041 | _ | _ | |a eng |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Halama, Niels |b 0 |
| 245 | _ | _ | |a Tumoral Immune Cell Exploitation in Colorectal Cancer Metastases Can Be Targeted Effectively by Anti-CCR5 Therapy in Cancer Patients. |
| 260 | _ | _ | |a Cambridge, Mass. |c 2016 |b Cell Press |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1524224608_29705 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a The immune response influences the clinical course of colorectal cancer (CRC). Analyzing the invasive margin of human CRC liver metastases, we identified a mechanism of immune cell exploitation by tumor cells. While two distinct subsets of myeloid cells induce an influx of T cells into the invasive margin via CXCL9/CXCL10, CCL5 is produced by these T cells and stimulates pro-tumoral effects via CCR5. CCR5 blockade in patient-derived functional in vitro organotypic culture models showed a macrophage repolarization with anti-tumoral effects. These anti-tumoral effects were then confirmed in a phase I trial with a CCR5 antagonist in patients with liver metastases of advanced refractory CRC. Mitigation of tumor-promoting inflammation within the tumor tissue and objective tumor responses in CRC were observed. |
| 536 | _ | _ | |a 314 - Tumor immunology (POF3-314) |0 G:(DE-HGF)POF3-314 |c POF3-314 |f POF III |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
| 650 | _ | 7 | |a CCL5 protein, human |2 NLM Chemicals |
| 650 | _ | 7 | |a CCR5 protein, human |2 NLM Chemicals |
| 650 | _ | 7 | |a Chemokine CCL5 |2 NLM Chemicals |
| 650 | _ | 7 | |a Chemokines |2 NLM Chemicals |
| 650 | _ | 7 | |a Cyclohexanes |2 NLM Chemicals |
| 650 | _ | 7 | |a Interferon-alpha |2 NLM Chemicals |
| 650 | _ | 7 | |a Neoplasm Proteins |2 NLM Chemicals |
| 650 | _ | 7 | |a Phenylurea Compounds |2 NLM Chemicals |
| 650 | _ | 7 | |a Pyridines |2 NLM Chemicals |
| 650 | _ | 7 | |a Receptors, CCR5 |2 NLM Chemicals |
| 650 | _ | 7 | |a STAT3 Transcription Factor |2 NLM Chemicals |
| 650 | _ | 7 | |a STAT3 protein, human |2 NLM Chemicals |
| 650 | _ | 7 | |a Triazoles |2 NLM Chemicals |
| 650 | _ | 7 | |a Clodronic Acid |0 0813BZ6866 |2 NLM Chemicals |
| 650 | _ | 7 | |a regorafenib |0 24T2A1DOYB |2 NLM Chemicals |
| 650 | _ | 7 | |a maraviroc |0 MD6P741W8A |2 NLM Chemicals |
| 650 | _ | 7 | |a NG-Nitroarginine Methyl Ester |0 V55S2QJN2X |2 NLM Chemicals |
| 700 | 1 | _ | |a Zoernig, Inka |b 1 |
| 700 | 1 | _ | |a Berthel, Anna |b 2 |
| 700 | 1 | _ | |a Kahlert, Christoph |b 3 |
| 700 | 1 | _ | |a Klupp, Fee |b 4 |
| 700 | 1 | _ | |a Suarez-Carmona, Meggy |b 5 |
| 700 | 1 | _ | |a Suetterlin, Thomas |b 6 |
| 700 | 1 | _ | |a Brand, Karsten |b 7 |
| 700 | 1 | _ | |a Krauss, Juergen |b 8 |
| 700 | 1 | _ | |a Lasitschka, Felix |b 9 |
| 700 | 1 | _ | |a Lerchl, Tina |b 10 |
| 700 | 1 | _ | |a Luckner-Minden, Claudia |b 11 |
| 700 | 1 | _ | |a Ulrich, Alexis |b 12 |
| 700 | 1 | _ | |a Koch, Moritz |b 13 |
| 700 | 1 | _ | |a Weitz, Juergen |b 14 |
| 700 | 1 | _ | |a Schneider, Martin |b 15 |
| 700 | 1 | _ | |a Buechler, Markus W |b 16 |
| 700 | 1 | _ | |a Zitvogel, Laurence |b 17 |
| 700 | 1 | _ | |a Herrmann, Thomas |b 18 |
| 700 | 1 | _ | |a Benner, Axel |0 P:(DE-He78)e15dfa1260625c69d6690a197392a994 |b 19 |u dkfz |
| 700 | 1 | _ | |a Kunz, Christina |0 P:(DE-He78)a9f6104e5c2c26345dcb242e6bdcb2b2 |b 20 |u dkfz |
| 700 | 1 | _ | |a Lücke, Stephan |0 P:(DE-He78)5bb4374f8998d504aa8d32fd671d5361 |b 21 |u dkfz |
| 700 | 1 | _ | |a Springfeld, Christoph |b 22 |
| 700 | 1 | _ | |a Grabe, Niels |b 23 |
| 700 | 1 | _ | |a Falk, Christine S |b 24 |
| 700 | 1 | _ | |a Jäger, Dirk |0 P:(DE-He78)ed0321409c9cde20b380ae663dbcefd1 |b 25 |e Last author |u dkfz |
| 773 | _ | _ | |a 10.1016/j.ccell.2016.03.005 |g Vol. 29, no. 4, p. 587 - 601 |0 PERI:(DE-600)2074034-7 |n 4 |p 587 - 601 |t Cancer cell |v 29 |y 2016 |x 1535-6108 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:125953 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 19 |6 P:(DE-He78)e15dfa1260625c69d6690a197392a994 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 20 |6 P:(DE-He78)a9f6104e5c2c26345dcb242e6bdcb2b2 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 21 |6 P:(DE-He78)5bb4374f8998d504aa8d32fd671d5361 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 25 |6 P:(DE-He78)ed0321409c9cde20b380ae663dbcefd1 |
| 913 | 1 | _ | |a DE-HGF |l Krebsforschung |1 G:(DE-HGF)POF3-310 |0 G:(DE-HGF)POF3-314 |2 G:(DE-HGF)POF3-300 |v Tumor immunology |x 0 |4 G:(DE-HGF)POF |3 G:(DE-HGF)POF3 |b Gesundheit |
| 914 | 1 | _ | |y 2016 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b CANCER CELL : 2015 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Thomson Reuters Master Journal List |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0110 |2 StatID |b Science Citation Index |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |
| 915 | _ | _ | |a IF >= 20 |0 StatID:(DE-HGF)9920 |2 StatID |b CANCER CELL : 2015 |
| 920 | 1 | _ | |0 I:(DE-He78)D120-20160331 |k D120 |l Angewandte Tumor-Immunität |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)C060-20160331 |k C060 |l Biostatistik |x 1 |
| 920 | 1 | _ | |0 I:(DE-He78)G010-20160331 |k G010 |l Geschäftsstelle |x 2 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)D120-20160331 |
| 980 | _ | _ | |a I:(DE-He78)C060-20160331 |
| 980 | _ | _ | |a I:(DE-He78)G010-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|